Information about Canagliflozin
Canagliflozin (kan" a gli floe' zin) is a specific SGLT-2 inhibitor that in clinical trials was shown to result in a reduction in serum HbA1c levels and improved glycemic control in type 2 diabetes, both as monotherapy (in patients who failed to achieve adequate control on diet and exercise) or in combination with insulin, metformin and/or sulfonylureas.
FDA approval information for Canagliflozin
Canagliflozin was approved for use in the United States in 2013 and current indications are for management of hyperglycemia in patients with type 2 diabetes in conjunction with diet and exercise and with or without other antidiabetic medications.
Dosage and administration for Canagliflozin
Canagliflozin is available in tablets of 100 and 300 mg under the brand name Invokana, the recommended dose being 100 to 300 mg once daily.
Combination drugs with Canagliflozin
Side effects of Canagliflozin
Common side effects include symptoms of thirst, urinary tract infections and mycotic genital infections. Less common side effects are hypoglycemia, dehydration, hypovolemia and serum creatinine elevations.
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Metiglinide Analogues
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors
Cost and Coupons - Canagliflozin
- GoodRx compare cost & coupons for Canagliflozin
- Find the lowest cost of Canagliflozin
- Search for Coupons for Canagliflozin
Reviews for Canagliflozin